KalVista to Support Global HAE Conference

KalVista Pharmaceuticals supports the third HAE Global Conference in Madrid, Spain, from 19-22 May 2016.

Andrew Crockett, KalVista’s CEO, said: “KalVista is delighted to support the HAE Global Conference, which aligns with our mission to provide oral treatments for HAE patients. We believe that an oral plasma kallikrein inhibitor provides a more convenient way to manage HAE and improve quality of life.”

The HAE Global Conference is organized by HAEi, the international umbrella organization for the world’s HAE patient groups. HAEi brings together patients, care givers, healthcare professionals, and industry representatives as a worldwide network dedicated to raising awareness of C1-inhibitor deficiencies. The HAE Global Conference program will include scientific and medical background on HAE, the most recent clinical and diagnostic advances, and advocacy strategies/techniques for gaining and broadening access to HAE medicines.

(Source: KalVista)